Retatrutide Retatrutide PRODUCT IMAGE
HPLC VERIFIED COA SUPPLIED ≥98.8% PURITY
— Metabolic

Retatrutide GLP-1 / GIP / Glucagon Triple Agonist

For in vitro research use only. Retatrutide is not for human or veterinary consumption, diagnosis, treatment, or prevention of any condition.

Retatrutide is a synthetic peptide that activates three different metabolic receptors (specialised docking points on cells) at the same time: GLP-1, GIP, and glucagon receptors. Each of these is involved in how the body manages energy, responds to insulin (the hormone that controls blood sugar), and processes fat. By targeting all three at once, it gives researchers a tool for studying how these pathways work together.

CAS Number
—
Molecular Formula
GLP-1/GIP/Glucagon agonist
HPLC Purity
98.8% (batch-verified)
Form
Lyophilised powder
Storage
2–8°C, desiccated, protected from light
Classification
Research reagent — in vitro use only

Research overview

Retatrutide is a synthetic peptide that simultaneously activates three distinct metabolic receptors: GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-dependent Insulinotropic Polypeptide), and glucagon receptors. Think of receptors like locks on the surface of a cell — this compound acts as a key that opens all three at once. Each receptor is involved in a different aspect of metabolic regulation: GLP-1 receptors are linked to insulin release and appetite signalling, GIP receptors to insulin response and fat storage, and glucagon receptors to blood sugar regulation and fat breakdown. Because it can activate all three pathways simultaneously, it gives researchers a tool for studying how these systems interact — something single-receptor compounds cannot replicate. It is among the most actively investigated next-generation metabolic research peptides. For research use only. Not for human or veterinary consumption.

Summary paraphrased from the peer-reviewed preclinical literature. Full citations will be available in the research library. For in vitro research use only.

Compound specifications

Common nameRetatrutide
Full nameGLP-1 / GIP / Glucagon Triple Agonist
CAS number—
Molecular formulaGLP-1/GIP/Glucagon agonist
Molecular weight4731.3 g/mol
SequenceModified 39-aa peptide — triple agonist
HPLC purity98.8% (batch-verified)
AppearanceWhite to off-white lyophilised powder
SolubilityBacteriostatic water, sterile saline
Storage (lyophilised)2–8°C, protected from light
Storage (reconstituted)2–8°C, up to 28 days
Supplied as10mg, 15mg, 20mg, 40mg Pen

Batch testing and certificate of analysis

Every batch of Retatrutide is third-party HPLC-tested prior to dispatch. A batch-specific certificate of analysis documenting HPLC purity, mass spectrometry confirmation, and appearance is supplied with every order.

Previous batch CoAs are archived in the CoA library. For batch-specific CoA requests prior to purchase, contact veloxpeps@gmail.com.

Frequently Asked Research-Use Questions

What purity is Velox Peptides Retatrutide?
Retatrutide is supplied at 98.8% HPLC-verified purity. A certificate of analysis is provided with every order. Every batch is third-party tested before dispatch.
How is Retatrutide supplied and reconstituted for research use?
Retatrutide is supplied as a lyophilised powder in sterile single-use vials. For in vitro research use, reconstitution is performed with bacteriostatic water. See the reconstitution calculator for volume calculations based on required concentration.
What is Retatrutide used for in preclinical research?
Retatrutide is studied in the peer-reviewed literature across the pathways described in the research overview above. Velox Peptides supplies Retatrutide strictly as a research reagent for in vitro use by qualified researchers. It is not a medicinal product and is not for human or veterinary consumption.

For in vitro research use only. Retatrutide is supplied solely as a research reagent for qualified professionals conducting in vitro or animal-model studies. It is not a medicinal product within the meaning of the Human Medicines Regulations 2012. It has not been evaluated by the MHRA or FDA. It is not intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Any use outside lawful scientific research is outside the scope of sale.

Compliance statement. Velox Peptides supplies research reagents for in vitro use by qualified researchers. Every compound is sold strictly as a research reagent. No product is a medicinal product within the meaning of the Human Medicines Regulations 2012. No product has been evaluated by the MHRA or FDA. No product is intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Any use outside lawful scientific research is outside the scope of sale. See our Research Use Policy and MHRA Statement.